Rocket


Overview
Financials
News + Filings
Key Docs
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


CNS Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
03/26/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Development Agreement between CNS Pharmaceuticals, Inc. and WPD Pharmaceuticals"
03/12/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals, Inc. Statements of Operations Year Ended Dec. 31, 2019 Year Ended Dec. 31, 2018 3 Mon. Ended Dec. 31, 2019 3 Mon. Ended Dec. 31, 2018 Operating expenses: General and administrative $ 1,978,643 $ 860,520 $ 1,039,337 $ 208,583 Research and development 1,854,334 21,267 1,484,394 – Total operating expenses 3,832,977 881,787 2,523,731 208,583 Loss from operations Other expense: Loss on settlement of liabilities – – Loss on change in fair value of SAFE agreements – – SAFE agreement expenses – – – Interest expense Amortization of debt discount – Total other expense Net loss $ $ $ Loss per share - basic and diluted $ $ $ $ Weighted average shares outstanding - basic and diluted 13,647,908 10,510,551 15,072,760 10,536,004 4 CNS Pharmaceuticals, Inc. Balance Sheets"
03/12/2020 10-K Annual Report for the period ended December 31, 2019
03/10/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals, Inc. Investor Presentation – March 2020"
03/02/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals, Inc. Investor Presentation – March 2020"
01/16/2020 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline"
01/16/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals, Inc. Investor Presentation – January 2020"
01/13/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals, Inc. Investor Presentation – January 2020"
12/20/2019 10-Q Quarterly Report for the period ended September 30, 2019
11/22/2019 8-K Quarterly results
11/13/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CNS Pharmaceuticals Announces Closing Of Initial Public Offering of Common Stock"
11/13/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/13/2019 3 Form 3 - Initial statement of beneficial ownership of securities:
11/08/2019 3 Priebe Waldemar (10% Owner) has filed a Form 3 on CNS Pharmaceuticals, Inc.
11/08/2019 3 Keyes Jeffry R. (Director) has filed a Form 3 on CNS Pharmaceuticals, Inc.
11/08/2019 3 Gumulka Jerzy (Director) has filed a Form 3 on CNS Pharmaceuticals, Inc.
11/08/2019 3 Evans Carl Anthony (Director) has filed a Form 3 on CNS Pharmaceuticals, Inc.
11/08/2019 3 Climaco John M (CEO) has filed a Form 3 on CNS Pharmaceuticals, Inc.
11/08/2019 3 Andraczke Andrzej (Director) has filed a Form 3 on CNS Pharmaceuticals, Inc.
11/08/2019 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
11/08/2019 EFFECT Form EFFECT - Notice of Effectiveness:
11/06/2019 CERT Form CERT -
11/05/2019 8-A12B Form 8-A12B - Registration of securities [Section 12(b)]:
10/10/2019 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
10/08/2019 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
07/16/2019 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
07/16/2019 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
06/28/2019 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
04/30/2019 C-AR Form C-AR - Annual Report:
10/26/2018 1-A/A Form 1-A/A - Offering Statement [Regulation A]: [Amend]
10/12/2018 1-A/A Form 1-A/A - Offering Statement [Regulation A]: [Amend]
06/15/2018 1-A Form 1-A - Offering Statement [Regulation A]:
06/15/2018 C-U Form C-U - Progress Update:
03/13/2018 C Form C - Offering Statement:

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy